Testosterone Propionate — Dosing, Cycles, Half-Life & Side Effects

Testosterone Propionate is an injectable testosterone ester with a half-life of 0.8 days. Short-acting testosterone ester for precise control. Complete HPTA shutdown occurs with any exogenous testosterone. Primary risks include strong HPTA suppression. This page is educational harm-reduction reference compiled from peer-reviewed literature — not medical advice, not an endorsement, not a recommendation to use. Consult a licensed clinician before any decision.

Quick Facts

ClassEsters
Half-life0.8 days
Detection window14 days
AromatizationYes
HepatotoxicityNone
Suppression10/10
17α-alkylatedNo
Administrationinjectable

Typical Dosing Ranges

Common dose range: 350-700mg/week

Cycle length: 8-12 weeks

Time to steady state: ~4 days

Dose ranges are compiled from published pharmacokinetic studies and community-reported usage. Where a value is community-reported rather than clinically studied, this page and its structured data flag it. Lower end of any range is always the safer starting point.

Stacking Considerations

  • No structural stacking blockers. Standard harm-reduction rules apply: minimize total androgen load, minimize oral exposure, and monitor bloodwork.

PCT Requirements

  • This compound causes clinically meaningful HPTA suppression. Post-cycle therapy is recommended.
  • Depot clearance estimate: ~4 days post-last-dose before SERM start (5 × apparent depot half-life of 19h).
  • Never stack two SERMs. Extend a single SERM (tamoxifen OR enclomiphene/clomiphene) rather than combining.
  • Use the cycle planner to generate a full protocol based on your complete stack, not this compound alone.

Side Effect Profile

  • Frequent injections
  • Water retention
  • Estrogen conversion
  • Suppression

Known Interactions

  • Testosterone Cypionate + Letrozole

    minor — pharmacokinetic

    Letrozole is potent AI. Over-suppression of estrogen is possible.

    Recommendation: Start with very low doses. Monitor E2 closely to avoid crash.

    Monitor: Estradiol, Joint pain, Mood

  • Testosterone Cypionate + Primobolan (Methenolone Enanthate)

    minor — synergistic

    Good synergy with low sides. Common stack.

    Recommendation: Generally well-tolerated combination.

    Monitor: Standard bloodwork

Related compounds

Monitoring (Bloodwork & Vitals)

  • Comprehensive metabolic panel (baseline, mid-cycle, post-cycle)
  • Lipid panel (total cholesterol, HDL, LDL, triglycerides)
  • CBC (hemoglobin, hematocrit — watch for erythrocytosis)
  • Sex-hormone panel (Total T, Free T, Estradiol sensitive, SHBG, LH, FSH)
  • Blood pressure (weekly self-check; flag systolic >140 or diastolic >90)

Baseline bloodwork is recommended before any cycle. Discontinue if liver enzymes exceed 3× upper limit of normal or if hematocrit exceeds 54%.

Frequently Asked Questions

What is the half-life of Testosterone Propionate?

Testosterone Propionate has a half-life of approximately 0.8 days. Clearance estimate: 19h � 5 = 95h = 4 days. This figure is used to determine injection frequency (for esters) and post-cycle clearance timing.

What is the typical dose range for Testosterone Propionate?

Commonly reported ranges for Testosterone Propionate: 350-700mg/week. Cycle length: 8-12 weeks. These are compiled from published studies and community-reported usage — individual response varies and lower end is always preferred.

Does Testosterone Propionate suppress natural testosterone?

Testosterone Propionate causes severe suppression of the HPTA axis (score 10/10). Post-cycle therapy (PCT) is recommended after use.

Does Testosterone Propionate aromatize to estrogen?

Aromatization profile: Yes. An aromatase inhibitor may be warranted if estrogen-related side effects appear — but AI use should be symptom-driven, not prophylactic, to avoid crashing E2.

What is Testosterone Propionate typically used for?

Testosterone Propionate is commonly used for: TRT, Bulking, Advanced users. Intended-use context does not imply safety — every use case carries the same underlying pharmacological risks.

Citations

  1. Behre HM et al.. 2004. Testosterone: Action, Deficiency, Substitution — Elimination half-life approximately 0.8 days IM as oil solution
  2. de Oliveira Vilar Neto JF et al.. 2021. Andrologia — Systematic review: only 4/38 known-outcome AAS-induced hypogonadism cases fully recovered
  3. Shankara-Narayana N et al.. 2021. J Endocrine Society — LH/FSH recovery approximately 52 weeks after 2 years testosterone undecanoate treatment
  4. Liu et al.. 2025. Substance Use & Misuse — AAS meta-analysis: SBP +12.43 mmHg (95% CI: 9.59-15.26), LDL-C +9.12 mg/dL (95% CI: 6.75-11.49)
  5. Bhasin S et al.. 2001. Am J Physiol Endocrinol Metab — Testosterone dose-response 25-600mg/week - propionate typically dosed 50-100mg EOD for equivalent weekly exposure
  6. de Oliveira Vilar Neto JF et al.. 2021. Andrologia — AAS-induced hypogonadism - propionate recovery comparable to other testosterone esters, 6-18 months
  7. Hartgens F, Kuipers H. 2004. Sports Medicine — Injectable testosterone propionate shows minimal hepatic impact; supports hepatotoxicity 0/10
  8. Bhasin S, et al. Testosterone therapy in men with androgen deficiency syndromes. J Clin Endocrinol Metab 2010

Disclaimer

StackItSmart is an independent harm-reduction reference. The content above is compiled from peer-reviewed literature and is not medical advice, not an endorsement, and not a recommendation to use Testosterone Propionate. Performance-enhancing compounds carry legal, endocrine, cardiovascular, and hepatic risks. Consult a licensed clinician before any decision. StackItSmart does not provide sourcing, procurement, or dosing prescriptions.

Skip to main content